Hypertrophic septal cardiomyopathy, the great simulator
DOI:
https://doi.org/10.47487/apcyccv.v2i4.171Keywords:
Cardiomyopathies, Hypertrophy, left ventricular, GeneticsAbstract
Hypertrophic cardiomyopathy is the more commonly (60 to 70 percent) genetically determined disease of the heart muscle caused by mutations in one of several sarcomere genes that encode components of the heart’s contractile apparatus. It is characterized by disproportionate hypertrophy in the absence of a secondary cause. The clinical presentation is variable, ranging from asymptomatic to heart failure or sudden cardiac death. Hypertrophy and abnormal ventricular configuration can result in dynamic left ventricular outflow obstruction in most cases. The goal of therapeutic interventions is largely to reduce dynamic obstruction, with different therapeutic options encompassing risk stratification for sudden death, genetic screening, lifestyle modifications, and drugs. A case of hypertrophic septal cardiomyopathy, a fairly frequent and under-diagnosed entity, is discussed below.
Downloads
References
Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Heart Fail. 2018;6(5):364-75. doi: 10.1016/j.jchf.2018.02.010.
Braunwald E. Hypertrophic cardiomyopathy: The first century 1869–1969. Glob Cardiol Sci Pract. 2012;2012(1):5. doi: 10.5339/gcsp.2012.5. eCollection 2012
Ingles J, Burns C, Barratt A, Semsarian C. Application of Genetic Testing in Hypertrophic Cardiomyopathy for Preclinical Disease Detection. Circ Cardiovasc Genet. 2015;8(6):852-9. doi: 10.1161/CIRCGENETICS.115.001093.
Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018;379(7):655-68. DOI: 10.1056/NEJMra1710575.
Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, et al. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2016;67(12):1399-409. doi: 10.1016/j.jacc.2016.01.023.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;76(25):e159-240. doi: 10.1016/j.jacc.2020.08.045. Epub 2020 Nov 20.
Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic Cardiomyopathy: Present and Future, With Translation Into Contemporary Cardiovascular Medicine. J Am Coll Cardiol. 2014;64(1):83-99. doi: 10.1016/j.jacc.2014.05.003.
Geske JB, Ong KC, Siontis KC, Hebl VB, Ackerman MJ, Hodge DO, et al. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J. 2017;38(46):3434-40. doi: 10.1093/eurheartj/ehx527.
Aslam F, Haque A, Foody J, Shirani J. The frequency and functional impact of overlapping hypertension on hypertrophic cardiomyopathy: a single-center experience. J Clin Hypertens (Greenwich). 2010;12(4):240-5. doi: 10.1111/j.1751-7176.2009.00251.x.
Konno T, Chang S, Seidman JG, Seidman CE. Genetics of Hypertrophic Cardiomyopathy. Curr Opin Cardiol. 2010;25(3):10.1097/HCO.0b013e3283375698. doi: 10.1097/HCO.0b013e3283375698.
Eijgenraam TR, Silljé HHW, de Boer RA. Current understanding of fibrosis in genetic cardiomyopathies. Trends Cardiovasc Med. 2020;30(6):353-61. doi: 10.1016/j.tcm.2019.09.003.
Piek A, de Boer RA, Silljé HHW. The fibrosis-cell death axis in heart failure. Heart Fail Rev. 2016;21(2):199-211. doi: 10.1007/s10741-016-9536-9.
Maron MS, Rowin EJ, Maron BJ. How to Image Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017;10(7):e005372. doi: 10.1161/CIRCIMAGING.116.005372.
Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021;18(6):1012-23. doi: 10.1016/j.hrthm.2021.01.019. Epub 2021 Jan 26.
